Gepotidacin: A Novel Therapeutic Agent for Gonorrhoea Treatment

Abstract

Gepotidacin is an exciting new oral antibiotic that\'s currently in Phase III trials, targeting uncomplicated urinary tract infections (UTIs) and urogenital gonorrhoea. 1.It works by blocking two essential topoisomerase enzymes that are vital for bacterial DNA replication. The early results from Phase II trials are looking quite promising, and if it gets approved, it could be the first new oral antibiotic for UTIs in over twenty years! To get a better understanding of how it interacts with other medications, Phase I studies were carried out with healthy volunteers to assess gepotidacin\'s drug drug interaction (DDI) profile. When taken with the CYP3A4/P-glycoprotein (P-gp) inhibitor itraconazole, there was a modest increase in the area under the curve (AUC) by about 48–50%. On the other hand, rifampicin, a strong CYP3A4 inducer, significantly reduced gepotidacin\'s plasma AUC by 52%, indicating a moderate DDI. No major interactions were observed with cimetidine, although some biomarkers suggested a partial inhibition of organic cation transporters. Interestingly, gepotidacin didn’t act as a DDI perpetrator for P-gp or CYP3A4, but it did slightly elevate the plasma levels of digoxin and showed weak inhibition of CYP3A4 when combined with midazolam. These insights will be crucial for ensuring the safe clinical use of gepotidacin alongside other medications.

Introduction

Antimicrobial resistance (AMR) among Gram-negative bacteria is a critical global health issue. Two common infections caused by these bacteria are urinary tract infections (UTIs), primarily from Escherichia coli, and urogenital gonorrhea, caused by Neisseria gonorrhoeae. Gonorrhea, a common sexually transmitted infection (STI), affects the genital tract, throat, or rectum and is increasing in incidence worldwide. If untreated, it can cause serious complications like pelvic inflammatory disease, infertility, and neonatal infections.

Historically, gonorrhea has been documented since ancient times, with social stigma and evolving treatments over centuries. Antibiotic resistance has steadily grown since the mid-20th century, making treatment more challenging. In Canada, resistance remains low, but ongoing surveillance and new therapies are essential.

Signs and Symptoms:

• In women: vaginal discharge, dysuria, pelvic pain, and signs of pelvic inflammatory disease if infection ascends.

• In men: painful urination, urethral discharge, epididymitis, and occasionally rectal symptoms.

Pathophysiology:
Infection begins with bacterial adhesion to mucosal surfaces via pili and surface proteins, enabling invasion of epithelial cells. The bacteria evade immune responses through antigenic and phase variation and can sometimes disseminate via the bloodstream causing systemic infections.

Treatment:
First-line treatment includes ceftriaxone combined with azithromycin. Alternatives include cefixime and gemifloxacin. Emerging treatments feature gepotidacin, a novel antibiotic targeting bacterial DNA replication enzymes differently than current drugs, showing promise against resistant strains.

Gepotidacin Details:
It disrupts DNA gyrase and topoisomerase IV, causing bacterial cell death without cross-resistance to fluoroquinolones. It has favorable pharmacokinetics and is undergoing clinical trials for UTIs and gonorrhea.

Conclusion

Gepotidacin represents a promising new approach to the treatment of gonorrhea, especially in the face of growing antimicrobial resistance. As a novel antibiotic targeting bacterial DNA gyrase and topoisomerase IV, it demonstrates efficacy against Neisseria gonorrhoeae, including strains resistant to current first-line therapies. Clinical trials have shown that gepotidacin offers an effective oral alternative with a favorable safety profile, making it a potential breakthrough in gonorrhea treatment. The rise of drug-resistant gonococcal infections poses a significant challenge to public health, and gepotidacin’s unique mechanism of action provides hope for overcoming this issue. Although further studies are needed to fully assess long-term safety, resistance development, and its role in combination therapies, gepotidacin holds the potential to significantly improve gonorrhea treatment and reduce the burden of resistance in the future. Ultimately, gepotidacin’s ability to address the urgent need for effective treatment options makes it a promising candidate in the ongoing fight against gonorrhea and antibiotic resistance

References

[1] GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2022; 400: 2221–48. [2] Centers for Disease Control and Prevention. Sexually transmitted disease surveillance. Availableat: https://www.cdc.gov/std/stats18/STDSurveillance2018-full-report.pdf. Accessed May 2023.9 [3] Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. [4] Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014 Jul;27(3):587-613. [PMC free article] [PubMed] [5] Ross JE, Scangarella-Oman NE, Flamm RK, Jones RN: Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol. 2014 Jul;52(7):2629-32. doi: 10.1128/JCM.00656-14. Epub 2014 Apr 23. [Article] [6] Collins JA, Osheroff N: Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance. ACS Infect Dis. 2024 Apr 12;10(4):1097-1115. doi: 10.1021/acsinfecdis.4c00128. Epub 2024 Apr 2. [Article] [7] Gibson EG, Bax B, Chan PF, Osheroff N: Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase. ACS Infect Dis. 2019 Apr 12;5(4):570-581. doi:10.1021/acsinfecdis.8b00315. Epub 2019 Feb 28.

Copyright

Copyright © 2025 Dr. Garlapati Usha Kiran, Guntru Pavan Kumar, Gollamudi Nehemiah, Kankanala Uma Satya Manikanta, Loya Pavan Kumar, Maareedu Mahesh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.